Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Nanowire Technology Developed to Detect Cancer Biomarkers in Urine

By LabMedica International staff writers
Posted on 04 Jan 2018
Analyzing microRNAs (miRNAs) within urine extracellular vesicles (EVs) is important for realizing miRNA-based, simple, and noninvasive early disease diagnoses and timely medical checkups.

A new approach for detecting cancer biomarkers in urine has been developed using a device composed of nanowires anchored into a microfluidic substrate. More...
This device enables EV collections at high efficiency and in situ extractions of various miRNAs of different sequences (around 1,000 types) that significantly exceed the number of species being extracted by the conventional ultracentrifugation method.

Scientists at Nagoya University (Furo-cho, Japan) and their colleagues fabricated nanowire-anchored microfluidic device for in situ extraction of urine EV–encapsulated miRNAs was fabricated by bonding the nanowire-embedded polydimethylsiloxane (PDMS) substrate and a herringbone-structured PDMS substrate. This new approach relies on playing the forces of negatively charged EVs off of positively charged nanowires to extract the miRNAs from the urine of patients with a variety of diseases. The team looked at samples from patients with pancreatic, liver, bladder, and prostate cancer, in addition to healthy subjects.

The scientists used a syringe pump to flow urine into the device, and then transferred the extracted samples on Toray's 3D-Gene microarray platform (Tokyo, Japan) for miRNA analysis by pipetting. Using the device, they were able to detect 1,106 different types of miRNAs in a single milliliter, versus an average yield of 200 to 400 miRNAs in total obtained using conventional methods, such as centrifugation.

The mechanical stability of the anchored nanowires during the buffer flow, as well as to the electrostatic collection of EVs onto the nanowires attributed to the success of the device. The approach yielded potential cancer-related miRNAs in urine for not only urological malignancies such as prostate cancer and bladder cancer, but also non-urological ones such as liver cancer and pancreatic cancer, the scientists believe it will be widely applicable.

Takao Yasui, PhD. an assistant professor and corresponding author of the study, said, “Our developed device could allow us to collect thousands of urinary microRNAs from only 1 mL of urine. Our new approach should allow scientists to move closer to the long-term goal of urinary miRNA-based early diagnoses and timely medical checkups for a variety of cancers.” The study was published on December 15, 2017, in the journal Science Advances.

Related Links:
Nagoya University
Toray Industries


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Lead author Professor Chamindie Punyadeera. (Image Credit: Griffith University)

Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules

Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more

Molecular Diagnostics

view channel
Image: Skin samples from people with a suspected genetic myopathy were examined for confirmation of disease. Brown spots show abnormal protein buildup inside the nuclei of cells (purple), typical of a type of myopathy called oculopharyngodistal myopathy. (Image Credit: Garvan Institute)

Long-Read Sequencing Test Identifies Genetic Causes in Inherited Muscle Disease

Inherited muscle diseases are highly heterogeneous and often progressive, leaving many patients without a molecular diagnosis despite extensive testing. Conventional assays typically target individual... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.